Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes
暂无分享,去创建一个
C. Vigouroux | M. Buyse | J. Gautier | M. Vantyghem | O. Lascols | C. Vatier | I. Jéru | A. Daguenel | D. Kalbasi
[1] M. Fasshauer,et al. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy , 2017, Endocrine.
[2] D. Dunger,et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline , 2016, The Journal of clinical endocrinology and metabolism.
[3] C. Musso,et al. Metreleptin Treatment in Three Patients with Generalized Lipodystrophy , 2016, Clinical medicine insights. Case reports.
[4] F. Travert,et al. One‐year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes , 2016, Diabetes, obesity & metabolism.
[5] E. Madrid,et al. Association of glycaemia with perceived threat of illness in patients with type 2 diabetes. , 2015, Primary care diabetes.
[6] M. Rijken,et al. Illness perceptions of cancer patients: relationships with illness characteristics and coping , 2015, Psycho-oncology.
[7] D. Frizelle,et al. Illness perceptions, mood and quality of life: a systematic review of coronary heart disease patients. , 2013, Journal of psychosomatic research.
[8] A. Wittkowski,et al. A Systematic Review of the Literature Exploring Illness Perceptions in Mental Health Utilising the Self-Regulation Model , 2013, Journal of Clinical Psychology in Medical Settings.
[9] R. Moss‐Morris,et al. Illness perceptions and glycaemic control in diabetes: a systematic review with meta‐analysis , 2011, Diabetic medicine : a journal of the British Diabetic Association.
[10] E. Martinez,et al. Lipodystrophy and quality of life of HIV-infected persons. , 2008, AIDS reviews.
[11] M. Atkinson,et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] S. Abbey,et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults , 2005, Quality of Life Research.
[13] Esteban Martínez,et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients. , 2002, Journal of acquired immune deficiency syndromes.
[14] O. Hanon,et al. Evaluation de l'observance du traitement antihypertenseur par un questionnaire : mise au point et utilisation dans un service spécialisé , 2001 .
[15] J. D. de Wit,et al. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. , 2001, AIDS.
[16] P. Stanley,et al. Illness perceptions and mood in chronic fatigue syndrome. , 2001, Journal of psychosomatic research.
[17] J. Treasure,et al. Perceptions of illness in individuals with anorexia nervosa: a comparison with lay men and women. , 2005, The International journal of eating disorders.
[18] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[19] O. Hanon,et al. [Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic]. , 2001, Presse medicale.
[20] J. Gatell,et al. Lipodystrophy Syndrome in Patients with HIV Infection , 2001, Drug safety.
[21] S. O’Rahilly,et al. Dunnigan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy. , 1997, QJM : monthly journal of the Association of Physicians.